Intracellular interleukin-1 receptor antagonist and uses thereof
US7482323B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 4, 2005 |
| Grant date | Jan 27, 2009 |
| Priority date | — |
| Expiry date | Jul 20, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/022
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Matrix metalloproteinases are major mediators of tissue destruction in various chronic inflammatory disorders. The present invention demonstrates that over-expression of intracellular isoform of IL-1 receptor antagonist confers to recipient cells resistance to signaling pathways of proinflammatory cytokines (such as tumor necrosis factor alpha and IL-1 beta) that induce matrix metalloproteinase and subsequent tissue degradation. Hence, over-expression of intracellular IL-1 receptor antagonist may inhibit tissue destruction in various inflammatory disorders such as rheumatoid arthritis, other arthritides, degenerative intervertebral disc disease and chronic skin ulcers that occurs in diabetes mellitus and bed-ridden patients.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.